Table 1 Clinical features of our patients.

From: Scalp HFO rates decrease after successful epilepsy surgery and are not impacted by the skull defect resulting from craniotomy

Pat. Nr

Sex

Etiology

Age at surgery, years

Resected area

Skull defect electrodes

Follow-up duration, years

Seizure outcome (Engel)

ASM withdrawn

1

f

Ganglioglioma

1.5

R temporal

T4

1.5

IV

No

2

f

Low-grade glioma

2.5

L frontal

None

1.7

Ia

No

3

f

FCD 2b

2.8

R frontal

Fz

1.7

IV

No

4

f

MOGHE

3.6

L frontal

Fz, F3, C3

1.6

Ia

No

5

f

Sturge Weber syndrome

3.8

R temporo-occipital

O2, P4

4.2

Ia

No

6

f

FCD 2a

5.3

R frontal

C4

1.3

IV

No

7

m

FCD 1a

7.8

L temporο-parieto-occipital

T3, F7

4.8

Ia

No

8

m

Ganglioglioma

10.5

L temporal

T5

1.8

Ia

Yes

9

f

Angiocentric glioma

11.4

R parietal

Oz, Pz

1.0

Ia

Yes

10

m

FCD IIa

13.0

L parietal

T3, F7

1.0

IV

No

11

m

Cavernoma

13.1

L frontal

None

2.8

Ia

Yes

12

f

Ganglioglioma

16.0

L temporal

T3, F7

2.7

Ia

Yes

13

f

Cavernoma

16.3

L frontal

None

2.5

Ia

Yes

14

f

FCD IIIb, ganglioglioma

16.5

R temporo-parietal

T6

2.0

Ia

Yes

  1. Clinical features include the etiological substrate, as verified by histopathology, the lobar localization and lateralization of the resected area, the skull defect electrodes in postsurgical EEG, the postsurgical seizure outcome, and the ASM status at last follow-up for each patient.
  2. Pat. Patient, nr number, m male, f female, FCD focal cortical dysplasia, MOGHE mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy, L left, R right, ASM anti-seizure medication.